



Biotech Daily

Wednesday June 24, 2015

Daily news on ASX-listed biotechnology companies

- * **ASX EVEN, BIOTECH UP: ANALYTICA UP 10%; BIOTRON DOWN 11%**
- * **NOVOGEN ANISINA (ATM-3507) KILLS MELANOMA IN MICE**
- * **ANAHEIM CALIFORNIA POLICE ASSESS DORSAVI VISAFE**
- * **BESTON BUYS PROBIOTIC DAIRY PROTEIN PLANT FOR \$7m**
- * **PHARMAUST RECEIVES \$329k FEDERAL R&D TAX REFUND**
- * **VIVO, GBS, PROLOG, ANONYMOUS SUBSTANTIAL IN AIRXPANDERS**
- * **QUEST, TROY CAIRNS TAKE 5% OF VIRALYTICS**
- * **3D RELEASES 114m ESCROW SHARES**
- * **PROTEOMICS RELEASES 175k ESCROW SHARES**

MARKET REPORT

The Australian stock market edged up 0.04 percent on Wednesday June 24, 2015 with the S&P ASX 200 up 2.5 points to 5,686.8 points.

Fifteen of the Biotech Daily Top 40 stocks were up, 12 fell, 11 traded unchanged and two were untraded.

Analytica was the best, up 0.1 cents or 10 percent to 1.1 cents, with 1.95 million shares traded.

Osprey climbed 8.4 percent; IDT was up 6.25 percent; Cellmid and Oncosil were up more than three percent; Acrux, Actinogen, Avita and Circadian rose more than two percent; Admedus, Anteo, Bionomics, Compumedics and Nanosonics were up more than one percent; with CSL and Starpharma up by less than one percent.

Biotron led the falls, down 1.5 cents or 10.7 percent to 12.5 cents with 4.2 million shares traded, followed by Benitec down 10.1 percent to 67 cents with 476,724 shares traded.

Uscom lost 9.5 percent; Viralytics fell 5.6 percent; Antisense fell 4.2 percent; Genetic Technologies was down 3.1 percent; Mesoblast and Tissue Therapies shed more than two percent; Clinuvel, Prima, Resmed and Sirtex were down more than one percent; with Cochlear and Medical Developments down by less than one percent.

NOVOGEN

Novogen says Anisina, formerly ATM-3507, has proved an effective anti-cancer agent against human melanoma in mice.

Novogen said that Anisina targeted the cytoskeleton of cancer cells and it had previously announced that it was active in-vitro against human melanoma cells, a cancer that is relatively insensitive to the taxanes and vinca alkaloids and killed human melanoma cells irrespective of their mutational status (BD: Apr 9,2015).

The company said that mice bearing the BRAF-mutant, human malignant melanoma cell line A-375 were treated with Anisina either intravenously at 60mg/kg twice weekly or orally at 100mg/kg daily).

Novogen said that both dosing regimens delivered a significant anti-tumor effect with no observed toxicity.

Novogen anti-tropomyosin program director Dr Justine Stehn said the result "clears the way for Anisina to enter the clinic".

"The potent effect observed here of the drug on a cancer as difficult to treat as malignant melanoma, combined with the lack of any obvious toxicity of the drug, justifies our earlier speculation that destroying a cancer cell's microfilaments would yield an equivalent therapeutic benefit to destroying the microtubules, but without the toxicity of the latter," Dr Stehn said.

Dr Stehn said that large-scale manufacture of the compound was underway with a first-in-man study planned to begin by July 2016.

Novogen was up one cent or 4.3 percent to 24.5 cents with 4.2 million shares traded.

DORSAVI

Dorsavi says the Anaheim Police Department in California will assess its Visafe wearble sensors to understand the physical strains of wearing protective equipment.

Dorsavi said it would provide a comparative analysis of the demands on police officers who wear two types of Sam Browne belts supporting police equipment and loadbearing ballistic vests, while undertaking a number of operational tasks.

The company said that of the City of Anaheim safety division wanted objective information relating to specific manual handling tasks of police officers, with a view to improving the welfare and safety of its police force, and the data would assist the City in considering more ergonomic equipment for employees of the Police Department.

Dorsavi said that Anaheim was the first police department to adopt its Visafe technology and the second US-based occupational health and safety customer following the signing of Caterpillar in May.

Dorsavi US president John Kowalczyk said that "progressive police departments across the country are becoming increasingly sophisticated in using informatics to protect the public".

"Now this is extending to informing a safe workplace," Mr Kowalczyk said.

"Dorsavi will provide the Anaheim Police Department with hard data to better understand the optimal way to safely equip its officers," Mr Kowalczyk said.

Dorsavi chief executive officer Dr Andrew Ronchi said the company was "seeing a growing number of customers committing to repeat projects with the commercial value of these projects growing exponentially".

Dorsavi was untraded at 26 cents.

PROBIOTEC

Probiotec says it has sold its Australian dairy protein (ADP) plant in Jervois South Australia to the Adelaide-based Beston Global Food Co for \$7 million.

Probiotec said the sale was subject to due diligence and was expected to be completed by September 30, 2015 and the agreement included provisions for it to continue obtaining immunoglobulins from the plant.

Probiotec fell three cents or 15 percent to 17 cents with 500 shares traded.

PHARMAUST

Pharmaust says it has received \$329,351 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Pharmaust said the rebate related to research and development activities for the year to June 30, 2014 by wholly-owned subsidiaries Epichem and Pitney Pharmaceuticals.

Pharmaust fell 0.1 cents or 11.1 percent to 0.8 cents with 2.7 million shares traded.

AIRXPANDERS

Airxpanders says that Melbourne's GBS Venture Partners, Vivo Ventures, Prolog Capital and a National Nominees account are substantial shareholders.

Airxpanders said that the Palo Alto, California-based Vivo became substantial on January 18, 2012 with 16,842,159 US shares equivalent to 50,526,477 Chess depository instruments (CDIs) or 23.92 percent; GBS became substantial on April 21, 2010 with 5,489,067 CDIs and 14,272,556 US shares equivalent to 42,817,668 CDIs or 22.86 percent; the London-based Prolog became substantial on March 13, 2009 with 6,778,169 US shares equivalent to 20,334,507 CDIs or 9.62 percent; and 'National Nominees' on behalf of an unnamed client became substantial on June 12, 2015 with 14,554,162 CDIs or 6.89 percent.

The company listed on the ASX on June 23 (BD: Jun 24, 2015).

Airxpanders was up three cents or 5.6 percent to 57 cents

VIRALYTICS

The Sydney-based Quest Asset Partners say it has become a substantial shareholder in Viralytics with 9,230,296 shares (5.02%).

In a substantial shareholder notice signed by the Quest director Troy Cairns, the company said it bought 4,386,375 shares for \$2,502,186 or an average price of 57 cents a share, between February 22 and June 22, 2015.

Quest said the registered holders of the shares were Invia Custodian Pty Ltd, State Street Australia, HSBC Custody nominees and National Nominees.

Viralytics fell four cents or 5.6 percent to 67.5 cents.

3D MEDICAL

3D Medical says that 113,947,446 shares were released from escrow on June 13 and June 23, 2015.

3D said that following the release of the shares, it would have 314,360,433 shares available for trading, with a further 58,748,168 shares held in ASX escrow until February 18, 2017, for a total of 373,108,601 shares on issue.

3D was up 1.5 cents or 14.3 percent to 12 cents.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says that 175,000 shares were released from escrow on June 23, 2015.

Proteomics said that following the release of the shares, it would have 18,925,000 shares available for trading, with a further 31,656,453 shares held in ASX escrow, for a total of 50,581,453 shares on issue.

Proteomics fell one cent or 2.3 percent to 43 cents.